-
Mashup Score: 0MATISSE: nivolumab in cutaneous squamous cell carcinoma - 8 month(s) ago
Charlotte Zuur, Leiden University Medical Centre, Leiden, The Netherlands, outlines the primary objectives and results of the Phase II MATISSE study (NCT02760498) of nivolumab and nivolumab plus ipilimumab (two monoclonal antibodies targeting PD1 and CTLA-4 respectively) in extensive cutaneous squamous cell carcinoma (SCC). The randomised trial enrolled 40 patients with an indication for curative surgery with or without radiotherapy; the study aimed to improve patients’ clinical prospects through immunotherapy and de-escalate surgery and radiotherapy. Dr Zuur shared the promising results of the immunotherapy, stating 90% of patients who refused surgery displayed disease-free survival of 1 year. This interview took place during the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Subgroup Observations From Missed KEYNOTE-789 Data in NSCLC Provide Insight for the Future - 8 month(s) ago
James Chih-Hsin Yang, MD, PhD, discusses the implications of the phase 3 KEYNOTE-789 trial and what directions investigators can examine in the future to help fill the unmet need for patients with TKI-resistant, EGFR-mutated metastatic non–small cell lung cancer.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Although KEYNOTE-789 missed both primary end points, patients with TKI-resistant, EGFR-mutated metastatic NSCLC had numerically prolonged survival with pemetrexed and chemotherapy with pembrolizumab. @ASCO #ASCO23 #ASCO2023 #lcsm https://t.co/QtBzIot15m https://t.co/peFutTiNo8
-
-
Mashup Score: 0
Emrullah Yilmaz, MD, PhD, Cleveland Clinic, Cleveland, OH, describes the rationale behind the addition of BCA101, a bifunctional EGFR/TGFβ inhibitor, with pembrolizumab, a PD-1 antibody, for patients with recurrent, metastatic head and neck squamous cell carcinoma (HNSCC) in a dose expansion trial (NCT04429542). EGFR is an established target, where existing therapies such as cetuximab target EGFR in head and neck cancer. Inhibition of TGFβ additionally has immunomodulatory effects. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥@YilmazMDPhD of @ClevelandClinic discusses combining BCA101 and pembrolizumab for recurrent HNSCC. A promising approach targeting EGFR and TGFβ: ➡️https://t.co/AQjf89AyVB⬅️ #ASCO23 #hncSM #ImmunoOnc
-
-
Mashup Score: 0
Administration of the anti–PD-1 antibody prolgolimab in combination with bevacizumab and platinum-doublet chemotherapy resulted in high response rates and a favorable safety profile in patients with recurrent or metastatic cervical cancer.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Administration of prolgolimab plus bevacizumab and platinum-doublet chemotherapy resulted in high response rates and a favorable safety profile in patients with recurrent or metastatic cervical cancer. @ASCO #ASCO23 #gyncsm https://t.co/xNyzE2CD70
-
-
Mashup Score: 0Maintenance Mirvetuximab Soravtansine Plus Bevacizumab Under Exploration in FRα+ Ovarian Cancer - 8 month(s) ago
The efficacy of maintenance mirvetuximab soravtansine plus bevacizumab is being compared with bevacizumab alone in patients with folate receptor alpha–positive recurrent platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancers that did not progress on second-line triplet therapy in the phase 3 GLORIOSA study.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The phase 3 GLORIOSA trial was designed to investigate the efficacy and safety of mirvetuximab soravtansine in combination with other standard agents like bevacizumab in FRα–positive gynecologic cancers. @ASCO #ASCO23 #gyncsm https://t.co/A4h73I3w2z https://t.co/hOkMoRLtjm
-
-
Mashup Score: 1
James L. Gulley, MD, PhD, reviews the safety and efficacy of PRGN-2009 alone and in combination with bintrafusp alfa in HPV-associated cancers and explains how this kind of approach may address an unmet clinical need.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
James L. Gulley, MD, PhD, reviews the safety and efficacy of PRGN-2009 alone and in combination with bintrafusp alfa in HPV-associated cancers and explains how it may address an unmet clinical need. @theNCI @ASCO #ASCO23 #ASCO2023 https://t.co/hkneFd0k1B
-
-
Mashup Score: 0VJOncology – The video journal of oncology - 8 month(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📣 September is Urological Cancer Awareness Month! Check out https://t.co/ys1d8pDAKO to see our extensive coverage of #GUCancer, such as our interview with @RavimadanDr on #prostatecancer during #ASCO23 👉 https://t.co/2n9pL8SB1C #GUsm #PCsm #uroonc https://t.co/8zrlL0Nn6U
-
-
Mashup Score: 0The role of SLAMF7-positive, CD8-positive T-cells in therapeutic resistance in kidney cancer - 8 month(s) ago
David A. Braun, MD, PhD, Yale School of Medicine, New Haven, CT, explains how a transitional study used advanced genomic techniques, such as single cell approaches, to uncover the causes of resistance to anti-PD1 therapy. Single cell RNA sequencing analysis from various clinical trial samples showed that slightly exhausted T-cells that expressed markers such as SLAMF7, were strongly linked with therapeutic resistance. This finding needs to be corroborated in other studies and requires functional testing, to uncover if this is a biomarker, predictive factor, or a component that can be modulated. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥@BraunMDPhD of @YaleMed discusses using single-cell approaches to understand resistance to anti-PD1 therapy in kidney cancer. More research is needed to confirm its significance: ➡️https://t.co/Bg75pxiQKf⬅️ #ASCO23 #kcsm #UroOnc #UroSoMe
-
-
Mashup Score: 0TACTI-002 Data Show Antitumor Activity With Second-Line Eftilagimod Alpha and PD-1 Inhibition in HNSCC - 8 month(s) ago
Bernard Doger de Spéville, MD, PhD, discusses the investigation of eftilagimod alpha plus pembrolizumab in the TACTI-002 trial, including prior evidence supporting this approach, the trial’s design and primary objective, and the combination’s efficacy and safety in both the head and neck squamous cell carcinoma and non–small cell lung cancer cohorts.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Bernard Doger de Spéville, MD, PhD, discusses the investigation of eftilagimod alpha plus pembrolizumab in the TACTI-002 trial. @DogerStart @Hospital_FJD @ASCO #ASCO23 #hncsm #oncology https://t.co/8IEluNva1q
-
-
Mashup Score: 0MAIN-CAV: maintenance cabozantinib and avelumab in urothelial cancer - 8 month(s) ago
Shilpa Gupta, MD, Cleveland Clinic, Cleveland, OH, talks on the trial design of the Phase III MAIN-CAV trial (NCT05092958) of maintenance cabozantinib and avelumab in patients with metastatic urothelial cancer. Based on the JAVELIN Bladder 100 trial (NCT02603432), maintenance avelumab is considered the standard of care in this setting, but responses remain poor in patients with certain metastases. The MAIN-CAV will assess the addition of cabozantinib in patients pre-treated with platinum-based chemotherapy, and overall survival will be the primary objective. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥@shilpaonc (@ClevelndClinic) discusses the Phase III MAIN-CAV trial, aiming to improve outcomes for patients w/ metastatic UC via maintenance cabozantinib and avelumab: ➡️https://t.co/qMCOgJ49Dg⬅️ #ASCO23 #ImmunoOnc #CTSM #UroOnc #UroSoMe #BlcSM
-
🎥Dr Charlotte Zuur (@LUMC_Leiden) discusses promising results from the Phase II MATISSE study using nivolumab and nivolumab plus ipilimumab in extensive cutaneous squamous cell carcinoma: ➡️https://t.co/RI7WRXGEL8⬅️ #ASCO23 #ImmunoOnc #SkcSM #CTSM #TrialUpdate